• Agendia BV, of Amsterdam, the Netherlands, closed a $23 million Series E round led by an undisclosed family investment firm that provided about half of the funds. Two independent entrepreneurs participated, with an investment of $1 million each, while the remaining capital was raised through Agendia's existing investor base. Proceeds will be used to accelerate the commercialization of MammaPrint, an in vitro diagnostic multivariate index assay cleared by the FDA to identify patients with early metastases who are likely to develop metastases within five years following surgery.